Oxford-based biotech company, Theolytics has announced the closing of a US $6.8 million (£5 million) Series A round.
The round was co-led by Epidarex Capital and Taiho Ventures LLC with participation from existing investor, Oxford Sciences Innovation (OSI).
The financing will be used to progress the company’s pipeline of candidates towards human clinical trials.
WHY IT MATTERS
Theolytics will...
